[1]唐 弦,赵智淏,李艺歆,等.我国罕见病目录疾病特征与药品治疗负担分析[J].卫生经济研究,2026,43(05):23-27.
 TANG Xian,ZHAO Zhihao,LI Yixin,et al.Analysis of Disease Characteristics and Drug Treatment Burden in China's Rare Disease Catalogues[J].Journal Press of Health Economics Research,2026,43(05):23-27.
点击复制

我国罕见病目录疾病特征与药品治疗负担分析

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
43
期数:
2026年05期
页码:
23-27
栏目:
疾病负担
出版日期:
2026-04-24

文章信息/Info

Title:
Analysis of Disease Characteristics and Drug Treatment Burden in China's Rare Disease Catalogues
作者:
唐 弦1赵智淏1李艺歆1胡 明1
1.四川大学华西药学院,四川 成都 610041
Author(s):
TANG Xian ZHAO Zhihao LI Yixin HU Ming
West China School of Pharmacy, Sichuan University, Chengdu Sichuan 610041, China
关键词:
罕见病罕见病目录疾病特征医疗保障经济负担
Keywords:
rare diseases rare disease catalogues disease characteristics medical security economic burden
分类号:
R95
文献标志码:
A
摘要:
目的:系统梳理我国两批罕见病目录的疾病特征、药物治疗情况及医保报销情况,为完善罕见病药品价值评估体系提供参考。方法:基于两批罕见病目录,梳理罕见病分类、主要发病年龄阶段、疾病严重程度以及药品疗效、治疗费用、医保报销情况。结果:两批目录内多数罕见病属于内分泌、营养和代谢疾病,在婴幼儿期高发,62种疾病有明确致死性,67种疾病可导致不同类型的残疾;约一半的疾病可以得到控制性治疗,仅少数疾病能根治;医保协议期内药品年均治疗费用约为11.92万元,绝大部分药品年均治疗费用在30万元以内,基本医保年均报销费用为7.51万元,患者年均自付费用为4.41万元。结论:罕见病具有发病年龄较小、病情严重等特点,基本医保虽然显著减轻了患者用药负担,但仍存在缺口,需健全多层次医疗保障体系,构建更科学的罕见病药品价值评估体系。
Abstract:
Objective To systematically review the disease characteristics, drug treatment status, and medical insurance reimbursement status of the two batches of rare disease catalogues in China. Methods Based on the two batches of rare disease catalogues, information was collected and analyzed on rare disease classification, major age of onset, disease severity, as well as drug efficacy, treatment costs, and medical insurance reimbursement status. Results The majority of rare diseases in the two catalogues were classified as endocrine, nutritional, and metabolic disorders, with a high incidence during infancy. Among the listed diseases, 62 were identified as fatal, and 67 could lead to various types of disability. Approximately half of the diseases could be managed with controllable treatment, while only a few could be cured. For drugs covered under the national medical insurance agreement period, the average annual treatment cost was approximately 119 200 yuan, with the vast majority having annual treatment cost below 300 000 yuan. The average annual reimbursement amount from basic medical insurance was 75 100 yuan, and the average annual out-of-pocket cost for patients was 44 100 yuan. Conclusion Rare diseases are characterized by relatively early age of onset and high severity, although basic medical insurance has significantly reduced the medication burden for patients, coverage gaps remain. It is necessary to establish a more diversified multi-tiered medical security system and construct a more scientific value assessment system for rare disease drugs.

参考文献/References:

[1] Ferreira C R. The burden of rare diseases[J]. American Journal of Medical Genetics, 2019, 179(06): 885-892.
[2] 《中国罕见病定义研究报告2021》发布[EB/OL].[2025-02-19]. http://health.people.com.cn/n1/2021/0913/c14739-32225468.html.
[3] Chen H, Xiang Y, Tang X, et al. Establishment of a value assessment framework for orphan medicinal products in China[J]. Orphanet Journal of Rare Diseases, 2024, 19(01): 390.
[4] 国家卫生健康委,科技部,工业和信息化部,等.关于公布第二批罕见病目录的通知:国卫医政发〔2023〕26号[A].2023.
[5] 国家卫生健康委,科技部,工业和信息化部,等.关于公布第一批罕见病目录的通知:国卫医发〔2018〕10号[A].2018.
[6] 刘慧玲,许春燕,姚卓君,等.我国罕见病用药保障机制:生产供应、价格保障及医保托底[J].卫生软科学,2025,39(06):80-84.
[7] 侯誉,热伊莎木·艾力,周丽,等.我国儿童罕见病治疗专用药及其医疗保障现状分析[J].医药导报,2025,44(12):1962-1970.
[8] 张森伟,陈非非,李凯渊,等.罕见病专项基金的国际经验及启示[J].医学与社会,2025,38(06):1-8.
[9] 过其祥,刘云鹏,朱珈震,等.基于Orphanet数据库的中国罕见病界定及累积时点患病率测算[J].中国新药杂志,2025,34(01):6-11.
[10] 焦杨,颜建周,李树祥.我国罕见病药物研发现状与技术领域分析——以第二批罕见病目录为例[J].中国新药杂志,2024,33(22):2305-2313.
[11] ICD-10医保版[EB/OL].[2025-08-04].https://code.nhsa.gov.cn/jbzd/ public/dataWesterSearch.html.
[12] 国家卫生健康委办公厅关于印发罕见病诊疗指南(2019年版)的通知[EB/OL].[2024-06-28].http://www.nhc.gov.cn/yzygj/s7659/201902/61d06b4916c348e0810ce1fceb844333.shtml.
[13] 国家卫生健康委办公厅关于印发软骨发育不全等86个罕见病病种诊疗指南(2025年版)的通知[EB/OL].[2025-08-12].https://www.nhc.gov.cn/yzygj/c100068/202507/5b3f41180a42465 eb9eec34597bacaf2.shtml.
[14] 桂俊峰,李京蔚,宋萃.罕见病诊疗现状及发展展望[J].临床医学进展,2024,14(04):681-688.

相似文献/References:

[1]胡善联.国内外罕见病的保障政策研究[J].卫生经济研究,2018,(05):3.
[2]陈馨仪,符 晓,王安石,等.罕见病患者治疗及保障研究[J].卫生经济研究,2020,(09):40.
 CHEN Xin-yi,FU Xiao,WANG An-shi,et al.Research on the Treatment and Guarantee of Patients with Rare Diseases[J].Journal Press of Health Economics Research,2020,(05):40.
[3]王子琪,闵连星,田兴军,等.我国罕见病医保政策的现状及优化路径[J].卫生经济研究,2021,38(11):22.
 WANG Zi-qi,MIN Lian-xing,TIAN Xing-jun,et al.The Situation and Optimization Path of Medical Insurance Policy for Rare Diseases in China[J].Journal Press of Health Economics Research,2021,38(05):22.
[4]李奕昊,唐贵忠.罕见病用药可负担性评价及医保政策研究[J].卫生经济研究,2022,39(4):53.
 LI Yi-hao,TANG Gui-zhong.Affordability Evaluation of Drugs for Rare Diseases and Research on Medical Insurance Policy[J].Journal Press of Health Economics Research,2022,39(05):53.
[5]张永理,张开然.我国罕见病患者医疗保障现状及改进建议[J].卫生经济研究,2023,40(1):53.
 ZHANG Yongli,ZHANG Kairan.Medical Security Status and Improvement Suggestions for Patients with Rare Diseases in China[J].Journal Press of Health Economics Research,2023,40(05):53.
[6]朱 坤sup>.中国罕见病保障机制:现状、挑战与建议[J].卫生经济研究,2024,41(01):23.
 ZHU Kun.Security Mechanism for Rare Diseases in China: Progress,Problems and Suggestions[J].Journal Press of Health Economics Research,2024,41(05):23.
[7]谭清立,丘丽莹.城市普惠型商业医疗保险比较研究[J].卫生经济研究,2024,41(02):23.
 TAN Qingli,QIU Liying.Comparative Study on Urban Inclusive Commercial Medical Insurance[J].Journal Press of Health Economics Research,2024,41(05):23.
[8]王珺琦,殷 悦,唐文熙.医保准入视角下罕见病用药经济价值评估的 难点、方法与建议[J].卫生经济研究,2024,41(09):58.
 WANG Junqi,YIN Yue,TANG Wenxi.Difficulties, Methods, and Suggestions for Assessing the Economic Value of Rare Disease Medications from the Perspective of Health Insurance Access[J].Journal Press of Health Economics Research,2024,41(05):58.
[9]林 星,董田甜.罕见病药品保障模式的国际经验与启示 ——以酶替代疗法药品为例[J].卫生经济研究,2024,41(11):54.
 LIN Xing,DONG Tiantian.International Experience and Enlightenment of Drug Security Model for Rare Diseases ——Taking Enzyme Replacement Therapy Drugs as an Example[J].Journal Press of Health Economics Research,2024,41(05):54.
[10]沈杨阳.中国罕见病问题及综合保障机制研究[J].卫生经济研究,2024,41(12):1.
 SHEN Yangyang.Study on the Problems of Rare Diseases and Comprehensive Protection Mechanisms in China[J].Journal Press of Health Economics Research,2024,41(05):1.

更新日期/Last Update: 2026-04-24